Patent classifications
G01N33/5029
METHOD OF MAKING TRITERPENOIDS FROM PETRI DISH CULTUREDANTRODIA CINNAMOMEA
A method of making triterpenoids from petri dish cultured Antrodia cinnamomea includes: A. providing petri dish cultured Antrodia cinnamomea in an extracting container; B. providing a supercritical solvent to the extracting container to obtain an Antrodia cinnamomea extract; sending the Antrodia cinnamomea extract to a chromatographic column to separate impurities and triterpenoids from the Antrodia cinnamomea extract, and removing the impurities, and collecting the triterpenoids containing fraction; and C. testing the bioactivity of the triterpenoids containing fraction by cytotoxicity test, cell morphology analysis, cell cycle and apoptosis test, and cell motility test to find an anti-cancer effect of the triterpenoids.
PREDICTION OF RESPONSE TO PARP INHIBITORS AND COMBINATIONAL THERAPY TARGETING C-MET AND PARP1
Provided herein are methods for identifying and treating cancers that are resistant to PARP inhibition. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. In some aspects. PARP inhibitor cancers are treated with a PARP inhibitor therapy in combination with a c-Met inhibitor therapy.
Microfluidic device for investigation of distance dependent interactions in cell biology
The invention presents a microfluidic device that provides investigation of distance dependent interactions between cells and various factors. A method that uses the device to determine distance dependent interactions between cells and various factors and agents that can change these interactions is also presented.
MODEL SYSTEMS FOR SCREENING MODULATORS OF mTOR SIGNALING
The presently disclosed subject matter relates to the generation of induced pluripotent stem cell (iPSC)-derived neuronal cell lines from subjects diagnosed with polyhydramnios-megalencephaly-symptomatic-epilepsy (PMSE) and assays making use of such cell lines to identify mammalian target of rapamycin (mTOR) signalling modulators as well as anti-epileptogenic compounds.
Microfluidic Chip For Analysis Of Cell Motility And Methods For Using Same
The present invention describes an integrated apparatus that enables identification of migratory cells directly from a specimen. The apparatus only requires a small number of cells to perform an assay and includes novel topographic features which can reliably differentiate between migratory and non-migratory cell populations in a sample. Both the spontaneous and chemotactic migration of cancer cells may be measured to distinguish between subpopulations within a tumor sample. The migratory cells identified using the apparatus and methods of the present invention may be separated and further analyzed to distinguish factors promoting metastasis within the population. Cells in the apparatus can be treated with chemotherapeutic or other agents to determine drug strategies to most strongly inhibit migration. The use of optically transparent materials in some embodiments allows a wide range of imaging techniques to be used for in situ imaging of migratory and non migratory cells in the apparatus. The apparatus and methods of the present invention are useful for predicting the metastatic propensity of tumor cells and selecting optimal drugs for personalized therapies.
NANO-ENGINEERED THERAPEUTIC STEALTH CELLS
Disclosed herein is a method of “reprogramming” highly motile cells found in tumors, such as these highly motile GSC and/or MDSC clones, into “auto-destructive” cell “missiles” (referred to herein as therapeutic stealth cells) that can seek and destroy new foci of recurrence within the body, such as the brain. Cells with enhanced motility can be sorted out from heterogeneous populations and then be rendered “auto-destructive” by deterministic delivery of an anti-cancer agent, such as an oncolytic virus plasmid cocktail.
FIBROSIS MODEL AND METHODS OF USE THEREOF
A method of screening a test compound, e.g., a fibrosis or IPF inhibitor, for induction of an unjammed-to-jammed transition (UJT) in fibrotic primary human bronchial epithelial cells (HBECs) isolated from a subject with a fibrotic lung disease includes culturing the fibrotic primary HBECs at an air-liquid interface for a time sufficient to provide a differentiated pseudostratified epithelium contacting the cultured cells with the test compound; and monitoring the motility of the cultured cells to identify the cultured cells as moving or stationary; wherein stationary cultured cells indicate that the test compound induces the UJT. Also included are methods of identifying lung fibrosis biomarkers.
AUTOIMMUNE ANTIBODIES FOR USE IN INHIBITING CANCER CELL GROWTH
The present disclosure provides, among other things, compositions (e.g., autoantibodies) that inhibit the growth, viability, or mobility of (invasion by) a cancer cell. Also provided are applications, such as therapeutic and diagnostic methods, in which the agents are useful, as well as screening methods for identifying autoantibodies useful in the applications.
CATSPER-ACTIVITY-TEST FOR DETERMINING MALE INFERTILITY
The present invention relates to an in vitro method for determining or diagnosing infertility of a male subject comprising the steps of (a) contacting a sperm sample obtained from said subject with a calcium-free test solution, (b) detecting the motility of the sperm in said sample under the test condition of step (a), and (c) determining infertility of the male subject based on the motility detected in step (b). Further, the present invention relates to a kit for use in a method for determining or diagnosing infertility of a male subject comprising (a) a calcium-free test solution, and (b) a calcium-containing control solution.
CHONDROITIN SULFATE GLYCOSAMINOGLYCAN HYDROGEL MATRICES FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
Disclosed herein are compositions and methods for cellular reconstitution of photopolymerized, lyophilized, bioactive chondroitin sulfate glycosaminoglycan (CS-GAG)-based hydrogel matrices.